A recent proposal that would allow the US federal government to set drug prices has been critiqued for being too small to meaningfully constrain costs. While this price control proposal would have a more limited impact when compared to some of the other recent price control proposals, it will have a broad and meaningful influence on investment decisions for all drugs in development. This type of policy achieves maximum distortion in future investment for minimal healthcare savings.
